Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
This randomized phase II trial studies how well combination chemotherapy (mFOLFIRINOX) with
or without hypofractionated radiation therapy before surgery works in patients with
pancreatic cancer that can be removed by surgery. Drugs used in combination chemotherapy,
such as oxaliplatin, leucovorin calcium, fluorouracil, and irinotecan hydrochloride, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Hypofractionated radiation therapy
delivers higher doses of radiation therapy over a shorter period of time and may kill more
tumor cells and have fewer side effects. It is not yet known if combination chemotherapy is
more effective with or without hypofractionated radiation therapy before surgery in treating
patients with pancreatic cancer.
Phase
Phase 2
Funding Agency/Sponsor
National Cooperative Group
Disease
Pancreatic, Liver, and Related Cancers
Enrollment Eligibility
Inclusion Criteria:
- Confirmation of radiographic stage as borderline resectable disease by real-time
Alliance central radiographic review
- No prior chemotherapy or radiation for pancreatic cancer
- No definitive resection of pancreatic cancer
- Chronic concomitant treatment with strong inhibitors of cytochrome p450, family 3,
subfamily a, polypeptide 4 gene (CYP3A4) is not allowed on this study; patients on
strong CYP3A4 inhibitors must discontinue the drug for 14 days prior to registration
on the study
- Chronic concomitant treatment with strong CYP3A4 inducers is not allowed; patients
must discontinue the drug 14 days prior to the start of study treatment
- No grade >= 2 neuropathy
- No known Gilbert's syndrome or known homozygosity for UGAT1A1*28 polymorphism
- No uncontrolled gastric ulcer disease (grade 3 gastric ulcer disease) within 28 days
of registration
- Not pregnant and not nursing; for women of childbearing potential only, a negative
pregnancy test done =< 7 days prior to registration is required
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Absolute neutrophil count (ANC) >= 1,500/mm^3
- Platelet count >= 100,000/mm^3
- Creatinine =< 1.5 x upper limit of normal (ULN) or
- Calculated (calc.) creatinine clearance > 45 mL/min
- Total bilirubin =< 2.0 mg/dL
- Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) =< 2.5 X upper limit
of normal (ULN)